Kewaunee Scientific heads into the final stretch of its fiscal year with the stock quietly recovering from a sharp earnings-driven selloff — and the market offering few clues about conviction on either side.
The price has done the talking recently. At $38.54, KEQU has gained 4.2% on the week and 12.3% over the past month, recovering ground lost after the March earnings report. That print was punishing: the stock fell more than 15% the day results dropped, and extended those losses to nearly 18.5% by the end of the following week, as investors digested diluted EPS of $0.23 — roughly half the year-ago figure — even as nine-month revenues climbed to $210.6 million from $163.3 million a year earlier. Revenue is growing; margins are not keeping pace.
Short interest tells a deliberately quiet story here. At 1.6% of the free float, bears have not made a meaningful bet against the stock. Short shares edged up roughly 2% in the latest session to about 46,600 — barely a rounding error for a $106 million micro-cap. The ORTEX short score of 46.3 is mid-range, ranking in the 29th percentile of its sector, and days-to-cover of 8.4 reflects the stock's thin liquidity rather than aggressive positioning. Borrow conditions are loose: the cost to borrow is running at 1.6% annualised, down roughly 14% on the week after touching a local peak above 2.9% earlier in April. Availability is ample relative to short interest, with lending pool demand nowhere near stressed levels.
The most notable institutional angle is one of studied patience. Minerva Advisors added over 41,000 shares through the end of December, bringing its stake to 4.3% of shares outstanding — a meaningful incremental commitment for a firm of its size in a stock this illiquid. Dimensional Fund Advisors added modestly in the most recent quarter, while Vanguard picked up just under 2,900 shares. Against that, the insider register tells a different story. The CEO, Thomas Hull, sold shares on multiple occasions between December and early January at prices between $37.50 and $39.00 — levels nearly identical to where the stock trades today. The CFO also sold in the same window. Neither sale was large in absolute terms, but the cluster of executive disposals near current prices is a fact the market has had time to absorb.
The mid-April appointment of Jorge Santos as Vice President of International Sales for the Laboratory Products Group is the only operational headline in recent weeks, signalling continued push on the international commercial side. It is a low-key announcement for a company whose international revenues have grown significantly, with nine-month sales up nearly 30% year-on-year — though the earnings composition of that growth is what investors will be scrutinising next.
Valuation and analyst data for KEQU are limited. No current analyst coverage or price targets are available in the data. The RSI at 57 suggests the stock is neither overbought nor oversold following its recent recovery. The next confirmed event is the Q4 fiscal 2026 earnings release, flagged for June 24 after market close. Given that the last two earnings events produced one-day declines of 5.6% and 15.3% respectively, and five-day declines running to 18.5% in the most recent quarter, the pattern of post-print weakness is one of the more consistent data points on this name. Whether the revenue momentum in Q4 translates into improved margins — and whether that is enough to break the post-earnings pattern — is what the June print will ultimately be measured against.
See the live data behind this article on ORTEX.
Open KEQU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
